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Introduction 
Gene delivery systems use a carrier to transport exoge-
nous genes as plasmid DNA (pDNA) to cells to produce 
an encoded protein, with the ultimate goal of altering 
endogenous gene expression and cell behavior with ap-
plications in functional genomics (Pannier et al., 2007), 
tissue engineering (Lu et al., 2013), medical devices 
(Zilberman et al., 2010), and gene therapy (Niidome 
and Huang, 2002). While nonviral gene delivery tech-
niques are less efficient than viral systems (Smith and 
Helenius, 2004), they are considered an attractive alter-
native because of low toxicity and immunogenicity, lack 
of pathogenicity, inexpensive synthesis, and easy mod-
ification (Boussif et al., 1995; Fasbender et al., 1997; He 
et al., 2010; Lv et al., 2006). Because of these advantages, 
empirical investigations into enhancing transfection of 
nonviral systems continue by means of modifying the 
pDNA carrier (Guo and Huang, 2012). However, those 
studies have had limited success in enhancing transfec-
tion largely due to the paucity of information on pre-
dicting relationships or interactions between parameters 
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Abstract 
Gene delivery systems transport exogenous genetic information to cells or biological systems with the potential 
to directly alter endogenous gene expression and behavior with applications in functional genomics, tissue en-
gineering, medical devices, and gene therapy. Nonviral systems offer advantages over viral systems because 
of their low immunogenicity, inexpensive synthesis, and easy modification but suffer from lower transfection lev-
els. The representation of gene transfer using models offers perspective and interpretation of complex cellu-
lar mechanisms, including nonviral gene delivery where exact mechanisms are unknown. Here, we introduce 
a novel telecommunications model of the nonviral gene delivery process in which the delivery of the gene to a 
cell is synonymous with delivery of a packet of information to a destination computer within a packet-switched 
computer network. Such a model uses nodes and layers to simplify the complexity of modeling the transfec-
tion process and to overcome several challenges of existing models. These challenges include a limited scope 
and limited time frame, which often does not incorporate biological effects known to affect transfection. The tele-
communication model was constructed in MATLAB to model lipoplex delivery of the gene encoding the green 
fluorescent protein to HeLa cells. Mitosis and toxicity events were included in the model resulting in simulation 
outputs of nuclear internalization and transfection efficiency that correlated with experimental data. A priori pre-
dictions based on model sensitivity analysis suggest that increasing endosomal escape and decreasing lyso-
somal degradation, protein degradation, and GFP-induced toxicity can improve transfection efficiency by three-
fold. Application of the telecommunications model to nonviral gene delivery offers insight into the development 
of new gene delivery systems with therapeutically relevant transfection levels. 
Keywords: nonviral gene delivery, transfection, HeLa, telecommunication modeling, nuclear plasmids, packet-
switched network
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of the delivery agents and the putative barriers to gene 
transfer (Azzam and Domb, 2004; Baker, 2004; Hag-
strom, 2000; Khalil et al., 2006; Medina-Kauwe et al., 
2005; Muller et al., 2007; Nishikawa and Huang, 2001; 
Wiethoff and Middaugh, 2003). 
While the exact mechanisms of the transfection pro-
cess are not fully understood, mathematical and compu-
tational models have been developed to provide insight 
into the process. For example, several pharmacokinetic 
studies have been instrumental in the development of 
computational models to describe and predict intracel-
lular behavior of the pDNA during transfection (Dinh 
et al., 2007; Hakamada and Miyake, 2012; Hume, 2000; 
Moroianu et al., 1996; Schwake et al., 2010; Varga et al., 
2001, 2005; Zelphati and Szoka, 1996). Such models in-
clude quantitative structure–activity relationships be-
tween vectors and transfection efficiency (Horobin and 
Weissig, 2005), kinetic models (Banks et al., 2003; Mori-
guchi et al., 2008; Roth and Sundaram, 2004; Varga et al., 
2001, 2005), stochastic stimulations (Dinh et al., 2007), or 
mechanistic modeling of transgene expression (Berra-
ondo et al., 2009). However, previous models that over-
simplify the complexity of gene delivery by compart-
mentalization (Banks et al., 2003; Ledley and Ledley, 
1994) or do not describe the entire transfection process 
(from internalization of gene to transgene expression) 
(Parra-Guillen et al., 2010) may lead to information loss 
or misinterpretation of results. For instance, many mod-
els partially describe nonviral gene delivery but biolog-
ical effects such as mitosis and toxicity, which greatly 
affect transfection, are not considered (Brunner et al., 
2000; Hakamada and Miyake, 2012; Lappalainen et al., 
1997; Li et al., 2004). Biological effects such as mito-
sis and toxicity are often not incorporated into existing 
models of gene delivery because those effects are gener-
ally observed within a time frame beyond that which is 
described by existing models (Banks et al., 2003; Varga 
et al., 2001, 2005). However, Jandt et al. (2011) have re-
cently developed a spatiotemporal model that includes 
mitosis and partitioning of the pDNA content to daugh-
ter cells; the model was able to recapitulate the in vitro 
experiments during a 48 h time frame for plasmid con-
tent in the cell nucleus. That model reinforces the need 
to incorporate biological effects into models of nonvi-
ral gene delivery, especially on time frames more rele-
vant to in vitro experiments. However, that model did 
not describe transgene production or incorporate toxic-
ity. Therefore, new models that can overcome the chal-
lenges of reconciling the entire transfection process 
while accounting for biologically relevant cellular pro-
cesses are needed in order to provide insight into the 
design of therapeutically relevant transfection systems. 
We have recently described the development of a 
new type of nonviral gene delivery model using tele-
communications theory (Wysocki et al., 2013), present-
ing an alternative modeling technique to open new 
perspectives and propose possible pathways for system-
atic improvement of nonviral gene delivery. The tele-
communications modeling technique has been used to 
describe other intricate “distribution systems,” such as 
data communication networks (Neuts et al., 1970), ser-
vicing of patients at hospitals (Kendall, 1953), and, more 
recently, the HIV infection process (Sharp et al., 2012), a 
process with many analogues to nonviral gene delivery. 
Here, we build on our telecommunication model of 
gene delivery, where delivery of pDNA to the cell nu-
cleus is considered in the same way as delivery of a 
packet of information (pDNA) to a destination computer 
(nucleus) within a random, packet-switched computer 
network (cell) where the intermediate nodes (barriers to 
pDNA transfer) decide randomly to which of the out-
going links the incoming packet should be sent (Neuts 
et al., 1970). In our model, we represent nonviral gene 
delivery as a digital process, since the events of pDNA 
transfer occur in terms of integers (e.g., complexes in-
ternalized, pDNA internalized into nucleus, transcrip-
tion from pDNA, etc.). Based on control theory and sys-
tems engineering, such digital systems that contain a 
small number of signals (e.g., plasmids, complexes, 
mRNA, proteins) are better described using digital mod-
eling techniques compared to modeling using differen-
tial equations (Ziemer et al., 1998). Also, in our model, 
we represent nonviral gene delivery as a stochastic and 
random process, where routing of the pDNA is random 
but with probabilities that are influenced by the sur-
rounding conditions. The same routing is described by 
random packet-switched computer networks, where the 
packet routing decision can be supported by the infor-
mation about the current state of the network or packet 
characteristics (Stallings, 2007). Therefore, since nonvi-
ral gene delivery acts a digital and random process, the 
system can be considered a “queue,” and therefore mod-
eled using the well-established queuing theory model-
ing techniques (Kendall, 1953). Our model describes the 
transfection process (from internalization to protein fold-
ing) over a period of days while simultaneously consid-
ering mitosis and toxicity, which are important cellular 
processes known to occur within that time frame and 
to affect transfection (Lappalainen et al., 1997; Li et al., 
2004). The telecommunication model was constructed 
in MATLAB by integrating pharmacokinetic parameters 
from literature with quantitative in vitro experiments. 
We then compare the telecommunication model in silico 
output to in vitro results for lipoplex-mediated deliv-
ery of pDNA encoding the enhanced green fluorescent 
protein (eGFP) gene to HeLa cells. A priori predictions 
based on sensitivity analysis suggest possible improve-
ments to the lipoplex gene delivery system to guide de-
signs of therapeutically relevant transfection systems. 
Theoretical Aspects 
To develop the novel model of DNA transfer, the non-
viral delivery process was first abstracted as a packet-
switched network. That telecommunication network 
was then implemented in MATLAB as a model by ap-
plying queuing theory to describe the arrival and de-
parture of information throughout the network. Finally, 
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because biological processes are highly parallel, the 
queue reduces the nonviral gene delivery abstraction to 
a pharmacokinetic model that is: (1) Poisson distributed 
to account for discrete (i.e., integer) numbers of pack-
ets, (2) a Markov process, in that the current state of the 
packets in the system will affect the current iteration of 
the simulation, (3) random distributed, in that probabil-
ities based on the pharmacokinetic values dictate rout-
ing, and (4) stochastic as noise is added to each pharma-
cokinetic parameter during each iteration. Therefore, we 
model nonviral gene delivery as a discrete and stochas-
tic process, unlike existing models that may be continu-
ous and/or deterministic (Banks et al., 2003; Brunner et 
al., 2000; Hakamada and Miyake, 2012; Lappalainen et 
al., 1997; Ledley and Ledley, 1994; Li et al., 2004; Parra-
Guillen et al., 2010; Varga et al., 2001, 2005). 
Packet-Switched Network 
The process of nonviral gene delivery was abstracted 
as a packet-switched network, in which delivery of ge-
netic information to the cell nucleus can be considered 
in the same way as delivery of a packet of information 
to the destination computer within a packet-switched 
network (Figure 1). In such a network, the data pack-
ets (i.e., pDNA or its altered form as mRNA or GFP) are 
transmitted through several intermediary nodes (rout-
ing through intermediate barriers) to ensure the packet 
payloads arrive intact at the destination (transgene 
product in the post-nuclear cytoplasm). The packets can 
be transmitted via different routes depending on the 
state of the nodes in the system and/or packet charac-
teristics (e.g. unpacked/packed state of complex, mark-
ing of molecules for degradation, presence of nuclear lo-
calization signals (NLSs), and nuclear breakdown). The 
nodes in this network represent components of the cell 
that act as servers (i.e., processing or altering of the in-
formation occurs) involved in pDNA transfer: milieu, 
endosome, lysosome, cytoplasm (before nucleus), nu-
cleus, and cytoplasm (after nucleus). Within each node 
are layers that dictate the processing of information con-
cerning the packet (pDNA, mRNA, GFP): physical layer 
is where movement of the packet occurs, network layer 
is where modification of the packet occurs, which af-
fects routing, transport layer controls the packet format 
(packed/unpacked/marked) and checks integrity (in-
tact/degraded), and the application layer uses the pDNA 
to create the specified functional protein that is encoded 
within the DNA. Each cell in the in silico experiment 
consists of such a network. The abstraction of the non-
viral gene delivery process in layers is more thoroughly 
described in our previous work (Wysocki et al., 2013). 
Queuing theory was then used to implement the net-
work as a model in MATLAB, as described next.   
Queuing Theory 
The packet-switch network was implemented in MA-
TALB using queuing theory. The pDNA arrival process 
was assumed to be random at the input of each node, 
and to follow a Poisson distribution. The Poisson distri-
bution is often used to model events that happen rarely 
but have very many opportunities to happen (Ross, 
2000), which is appropriate for a pDNA delivery sys-
tem where around 1% of the initially delivered pDNA 
makes it to the nucleus (Tachibana et al., 2004). The ar-
rival distribution is characterized by a rate parameter λ, 
with outcomes λ = 1 for success with probability P, and 
λ = 0 for failure with probability q = 1 − P, where 0 < P < 1. 
The expected value of λ is E(λ)=P Thus, the expected 
number of successes (i.e., input of one DNA complex, 
pDNA, mRNA, or GFP into the next active node) in a 
single service is the probability that the trial will be a 
success. Therefore, the number of arrivals in any given 
time interval (t, t + τ) follows a Poisson distribution with 
a parameter (λτ), such that  
              P[(N(t + τ) – N(t)) = k] = e
–λτ (λτ)k  (1)                        k!                                 
where e is the base of the natural logarithm 
(e = 2.71828…) and N(t + τ) − N(t) = k is the number of ar-
rivals in the interval (t, t + τ). The arrival process was 
modeled as an inhomogeneous Poisson process, with 
Figure 1. Modeling nonviral gene delivery as a packet-switched network. Each barrier of the gene delivery process is represented by an individual 
node containing layers, which dictate transmission of the data packet, that is, pDNA transfer (see Theoretical Aspects section). The physical layer 
(P) is where movement of the packet occurs. The network layer (N) is where modification of the packet occurs, which affects addressing or rout-
ing. The transport layer (T) controls the packet format and checks integrity. The application layer (A) uses the information encoded in the delivered 
packet (complex, pDNA, mRNA, or GFP) to perform a desired operation.   
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the intensity λ(t) being a function of time. In such a pro-
cess, the expected number of events within a time inter-
val (a, b) is:
  λa,b = ∫a
b
 λ(t) dt                                     (2) 
and the number of arrivals in that time interval  
P[(N(b) – N(a)) = k] = e
-λa,b  λ
k
a,b
       k!                k = 0, 1, 2, …       (3) 
The arrival process of the pDNA or complex at each 
node is also modeled as a Markov process in which the 
outcome of distributions for the data packets are only 
dependent on the previous simulated state of the net-
work, and therefore memoryless (Ross, 2000). 
After arrival of the packet at each node, the pDNA or 
DNA complex is serviced (i.e., processed) with an ex-
ponentially distributed service time, µ, also modeled as 
a Markov process. The exponential distribution is de-
scribed by the probability density function:  
      –µx,       x ≥ 0
          f(x; µ) = { µe      0,           x < 0    (4) 
Biological processes can be considered as highly par-
allel; therefore the number of customers (DNA complex, 
pDNA, mRNA, GFP) < servers (nodes), which results 
in a total departure or instantaneous service rate equal 
to (nµ), where n is the number of complexes, pDNAs, 
mRNAs, or GFPs being serviced (i.e., processed at each 
node) at each time intervals. Therefore the output from 
one node and input into the next intermediate node fol-
lows a Poisson distribution, where λ(t) = µ(t), allow-
ing the packet-switched network to be represented as a 
pharmacokinetic model with service rates (i.e., process-
ing at each node) equal to the kinetic constants avail-
able in literature (Table I). Since the actual kinetic could 
be higher or lower than the reported average, µ(t) was 
implemented in the model to change randomly around 
the respective mean values, as 10% standard deviation 
with Gaussian distribution, thereby creating a stochastic 
system. When multiple routes for the packet are avail-
able, a probabilistic directing of services was used as 
previously described (Wysocki et al., 2013). The same 
approach for directing of services was used in a spa-
tiotemporal model of gene delivery (Jandt et al., 2011). 
Therefore, using queuing theory, the abstracted packet-
switched network of the gene delivery process (Figure 
1) can be represented as a pharmacokinetic model that is 
discrete and stochastic (Figure 2; see below).      
Pharmacokinetic Model 
The nonviral gene delivery process was represented as 
a reactive system (Fisher and Henzinger, 2007), where 
each process may change state in reaction to another 
process changing state (Figure 2). The processes in-
cluded in this model are internalization, endosomal 
escape, lysosomal degradation, binding of nuclear im-
port proteins (complexes), unpacking of pDNA from 
DNA carrier, nuclear pore import (pDNA or com-
plexes), degradation of unpacked pDNA, binding of 
nuclear import proteins (pDNA), nuclear-area localiza-
tion during mitosis, nuclear localization, detachment 
of nuclear import proteins (pDNA or complexes), tran-
scription, mRNA degradation, translation, protein (un-
folded) degradation, protein maturation, and protein 
(folded) degradation. The rates at which these processes 
occur are identified in the literature (see references in 
Table I), but distributed as described above. Based on 
the available first-order kinetics for each process (Ta-
ble I), the simplest model was developed, in terms of 
accounting for the key processes in an even more com-
plex DNA transfer process. Such a computational model 
is well suited to representing a complicated chain of 
events, even when not every detail about the process is 
known (Fisher and Henzinger, 2007). 
Methods 
Computational Model 
Queuing theory was used to model the telecommuni-
cations packet-switched network in MATLAB (Neuts 
et al., 1970), as described above. Model simulations 
were run in ½ second increments while keeping track 
of subcellular distribution data of the complex, pDNA, 
mRNA, and protein for each cell in the experiment 
at each time increment. The averages of the subcellu-
lar distribution data of all the cells in the experiment at 
each time increment was collected as an averaged sin-
gleton. For sensitivity analyses, main effect sensitiv-
ity Sj for the model of k inputs to transfection output of 
y = f(µ1, µ2, …, µk) was calculated as follows:  
      
Sj =
 | (V(Ey|µj))| ×     1                       V(y)  2 µj0.0s′           j = 1, 2, …, k  (5)
where E(y) is the expected value of y, V(y) is the vari-
ance of the model output y, and V(E(y|µj) is the variance 
of the expected value of y conditional on values of input 
j (Mokhtari et al., 2006). For all in silico simulations, the 
initial number of cells in the experiment was set to 5,000. 
For in silico and in vitro experiments lipoplexes were al-
lowed to remain in contact with the cells for 4 h. Within 
the model, successful transfection is achieved when 
the number of GFP molecules in a cell reaches three or 
greater, since the fluorescence from multiple GFP mole-
cules provides a stronger signal than a single GFP (Cinelli 
et al., 2000) and, therefore, in silico transfection will more 
closely resemble in vitro transfection measurements us-
ing fluorescence cytometry (see below). 
Cell Culture and Transfection 
HeLa cells (ATCC, Manassas, VA) were cultured in 
T-75 flasks in Dulbecco’s Modified Eagle’s Medium 
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(DMEM, Gibco/Invitrogen, Carlsbad, CA) contain-
ing 4.5 g/L glucose, supplemented with 10% fetal bo-
vine serum (Gibco), 2 mM L-glutamine (Gibco), and 
100 units/mL of penicillin/streptomycin (Gibco) and 
maintained at 37°C in a humidified 5% CO2 atmosphere. 
Cells were dissociated at confluence with 0.05% Tryp-
sin-EDTA and viable cells were counted using a hemo-
cytometer and trypan blue dye exclusion assay. Cells 
were seeded at a density of 28,000 cells/cm2 for flow cy-
tometric analysis and WST-1 assays (in 300 µL into wells 
of a 48-well plate; see below) and for nuclei isolation 
(in 10 mL into T-75 flasks; see below). After cell adher-
ence (~18 h after cell seeding), lipoplexes were formed 
and delivered to the cells at a volume of 100 µL/cm2 and 
a dose of 0.27 µg/cm2. Plasmid pEGFPLuc, which en-
codes for both the eGFP and firefly luciferase protein 
(LUC) under the direction of a CMV promoter (Clon-
tech, Mountain View, CA) was used for all transfection 
experiments. Plasmids were purified from bacteria cul-
ture using Qiagen (Valencia, CA) reagents and stored in 
Tris–EDTA buffer solution (10 mmol/L Tris, 1 mmol/L 
EDTA, pH 7.4) at −20°C. Lipoplexes were formed with 
Lipofectamine 2000 (LF2000; Invitrogen), following 
manufacturer’s instructions. Briefly, DNA complexes 
were formed at a pDNA: lipid ratio of 1:1.3 (w/v) in se-
rum-free OptiMEM media (Invitrogen) by adding trans-
fection reagent diluted in media dropwise to pDNA 
diluted in media, mixing by gentle pipetting, and incu-
bating for 20 min. Lipoplexes were allowed to remain in 
contact with the cells for 4 h, and then the media was as-
pirated, cells were rinsed once with 1× PBS, and fresh 
medium added to the cells. Control flasks were seeded 
Table I. Summary of kinetic parameters used for model (see Figure 2)
Kinetic parameter description Rate k (s−1) Reference
µ1 Internalization 1.45 Calculated from Lipofectamine delivery of pWizβGal under direction of CMV pro-
moter to HEPG2/C3A cells (Varga et al., 2005)
µ2 Endosomal escape 1.7 × 10
−4 Calculated from ODN release from DOSPA/DOPE lipoplexes (Lappalainen et al., 
1997); used to model lipoplex gene delivery (Varga et al., 2001)
µ3 Lysosomal degradation 3.33 × 10
−4 Reported to be experimentally found and used to model Lipofectamine delivery of 
pWizβGal to HEPG2 cells (Varga et al., 2005)
µ4 Attachment of importins (complexes) 1.7 × 10
−3 Estimated from the kinetic parameter from adenoviral vector kinectics which show 
similar kinetics as lipoplexes until post nuclear events (Varga et al., 2005), con-
sistent with a recent report (Rehman et al., 2013)
µ5 Unpacking of pDNA 3.5 × 10
−3 Calculated from FRET signal quenching of synthesized unilamellar vehicles added 
to DOTAP/ODN lipoplexes (Zelphati and Szoka, 1996)
µ6 Nuclear pore import 5.0 × 10
−5 Reported to be experimentally found and used to model Lipofectamine delivery of 
pEGFP-C1 to HEPG2 cells (Varga et al., 2001)
µ7 Degradation of pDNA 8.3 × 10
−5 Calculated by FISH for pGL2 encoding luciferase (Lechardeur et al., 1999); similarly 
reported elsewhere (Dean et al., 1999) and used to model Lipofectamine delivery 
of pWizβGal to HEPG2 cells (Varga et al., 2001)
µ8 Attachment of importins(pDNA)  3.3 × 10
−5 Reported to be found and used to model Lipofectamine delivery of pEGFP-C1 to 
HEPG2 cells (Varga et al., 2001) and consistent with a report of unpacking of 
PNA-labeled pDNA in HeLa cells (Wilson et al., 1999).
µ9 Nuclear-area localization during mitosis 2.8 × 10
−4 Calculated from LF2000 delivery of pCMV-Venus yellow fluorescent protein to HeLa 
cells using time lapse images (Hakamada and Miyake, 2012).
µ10 Nuclear localization 1.7 × 10
1 Reported to be experimentally found and used to model Lipofectamine delivery of 
pWizβGal to HEPG2 cells (Varga et al., 2001).
µ11 Detachment of importins 1.7 × 10
1 Reported to be found (Moroianu et al., 1996) and used to model Lipofectamine de-
livery of pWizβGal to HEPG2 cells (Varga et al., 2001)
µ12 Transcription 5.0 × 10
−2 Reported to be experimentally found from time lapse images and theoretical models 
of GFP expression in BEAS-2B cells transfected with LF2000 (Schwake et al., 
2010). The value of this parameter is consistent with other reports (Hume, 2000).
µ13 mRNA degradation 2.8 × 10
−5 Calculated from GFP mRNA stability experiments using Northern blot (Sacchetti et 
al., 2001); also used in theoretical models of GFP expression in BEAS-2B cells 
transfected with LF2000 (Schwake et al., 2010).
µ14 Translation 2.8 × 10
−2 Reported to be found from time lapse images and theoretical models of GFP expres-
sion in BEAS-2B cells transfected with LF2000 (Schwake et al., 2010); consistent 
with other reports in literature (Alberts, 1994)
µ15 Protein (unfolded) deg. 1.4 × 10
−4 Reported to be found from time lapse images and theoretical models of GFP expres-
sion in BEAS-2B cells (Schwake et al., 2010)
µ16 Protein maturation 2.8 × 10
−4 Calculated from time for chromophore formation in presence of inclusion bodies 
(Sniegowski et al., 2005). The value of this parameter was also used in theoreti-
cal models (Schwake et al., 2010).
µ17 Protein (matured) degradation  3.6 × 10
−6 Calculated from GFP protein stability experiments using Western blot (Sacchetti et 
al., 2001). A similar value for this parameter was also used in theoretical models 
(Schwake et al., 2010).
The parameter values are first-order rate constants and therefore have units of s−1. CMV, cytomegalovirus; DDAB, monocationic dimethyl-diocta-
decylammonium bromide; DOPE, dioleoyl-phosphatidylethanolamine; DOSPA, polycationic 2,3-dioleoyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-
dimethyl -1-propanaminium trifluoroacetate; LF2000, Lipofectamine®2000; ODN, oligodeoxynucleotide.
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as described above, without the addition of lipoplexes. 
Cells were then assayed for proliferation, toxicity, trans-
fection efficiency, and nuclear plasmids (see sections 
below). 
WST-1 Cell Proliferation and Toxicity 
Cells were seeded and transfected as described 
above. Medium was removed, cells were rinsed with 
200 µL 1× PBS, and 200 µL WST-1 solution (WST-1 re-
agent [Clontech] diluted 1:9 in phenol-free DMEM 
[Gibco]) was added to cells at 5, 13, 21, and 45 h post-de-
livery of the lipoplexes (treated) or without lipoplexes 
(control). Three hours after addition of WST-1 solution, 
absorbance measurements were taken at 430 nm (refer-
ence 690 nm; background adjusted to WST-1 solution-
only wells). An n = 6 was used for treated conditions and 
n = 3 was used for control conditions. 
Transfection Efficiency and Flow Cytometric Analysis 
Cells were seeded and transfected as described 
above. Transfection efficiencies were assayed at 8, 16, 
24, and 48 h post-delivery of the lipoplexes using flu-
orescence activated cell sorting (FACS). At each time 
point indicated, cells were dissociated with the addi-
tion of 0.05% Trypsin-EDTA, followed by inactivation 
of enzyme with addition of an equal volume of com-
pleted media, and then three wells of a 48-well plate 
were pooled and placed on ice for a single sample, n = 1. 
Flow cytometric analysis was performed using a Cytek 
DxP10 cell counter (University of Nebraska-Lincoln’s 
Center for Biotechnology Flow Cytometry Core Facil-
ity), with detection of GFP with excitation at 488 nm and 
emission at 530 ± 15 nm. A live gate was set in forward 
scatter (FSC) versus side scatter (SSC) plot to remove 
cell debris or clumped cells from the count. The number 
of GFP positive cells counted was divided by the total 
cell count (a minimum of 5,000 gated cells counted) and 
reported as transfection efficiency. Counts from an n = 6 
was collected at each time point. 
Nuclei Isolation and Plasmid Quantification 
Cells were seeded and transfected as described above. 
Nuclei were isolated, purified, and the number of pEG-
FPLuc plasmids per cell nucleus was found at 8, 16, and 
24 h post-delivery. Nuclei were isolated from cells in 
two, pooled T-75 flasks using a using an iodixanol gra-
dient, as previously described (Cohen et al., 2009). Nu-
clei isolation was confirmed by Hoechst stain and flu-
orescence microscopy (data not shown). Nuclei were 
lysed with 0.5% sodium dodecyl sulfate and DNA was 
collected in the aqueous phase by phenol extraction 
and further purified by collecting the aqueous phase 
and performing a second extraction with 25:24:1 phe-
nol/chloroform/isoamyl alcohol (Thermo-Fisher). Af-
ter an ethanol precipitation the DNA was suspended 
in DEPC. Quantification of nuclear plasmids was per-
formed by a previously described method (Cohen et 
al., 2009) using qPCR to determine the number of cop-
ies of the plasmid, modified by normalization method in 
which the number of cells was determined by using the 
slope obtained for eGFP curve to convert CT value ob-
tained for ACTA1 to copy number. ACTA1 was assumed 
to be a single copy gene and to have the same qPCR ef-
ficiencies as eGFP (Cohen et al., 2009), therefore every 
two copies of ACTA1 represent 1 cell in the experiment. 
Primers (IDT, Skokie, IL) used were ACTA1 Forward 
5′-TCAGAAAGATTCCTACGTGGGCGA-3′, ACTA1 
Reverse 5′-TGTGGTGCCAGATCTTCTCCATGT-3′ and 
eGFP (Hama et al., 2007). An n = 6 was used for all time 
points. 
Results and Discussion 
Initial Model Performance 
Development of the model is detailed in the Theoret-
ical Aspects section of this work. After reconciling the 
reported kinetics (Table I) into the telecommunication 
model, little difference between in silico and in vitro 
transfection efficiency is observed early after DNA de-
livery, with both model and experimental data show-
ing ~20% transfection efficiency 10 h after treatment 
with complexes (Figure 3A). Previous models have been 
developed to represent transfection consistent with 
this time frame and report similar agreement between 
model output and in vitro results (Banks et al., 2003; 
Varga et al., 2001). However, our model reported nearly 
100% transfection after 48 hours (Figure 3A), a prodi-
gious overestimate of transfection efficiency, which 
was measured as ~30% after 48 h. The overestimation of 
Figure 2. Routing of nonviral complexes. After delivery and arrival to 
cells, the pDNA will route differently in the packed state, unpacked 
state, or if the cell is undergoing mitosis. Routes that are active during 
mitosis are indicated by dashed lines. Kinetic parameters are shown 
in Table I. Mitosis rate was determined by WST-1 assay (see Supple-
mentary Figure S1 and Methods section). apacked plasmid; bunpacked 
plasmid; cnuclear import binding proteins; dnuclear pore complex; em-
RNA; funfolded protein; gfolded protein; δ indicates degradation.   
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transfection by the telecommunication model can likely 
be attributed to the ability of retransmitting those com-
plexes, pDNAs, or mRNAs that fail to progress past a 
barrier at an earlier time point, provided degradation 
has not occurred. Retransmission occurs biologically 
and is executed easily in a telecommunications compu-
tational model (Fisher and Henzinger, 2007), but most 
models follow deterministic mathematical rules where 
the algorithm fails to describe retransmit ability (Banks 
et al., 2003; Parra-Guillen et al., 2010; Varga et al., 2001, 
2005). Given the overestimation of transfection with the 
first version of our telecommunications model, a typical 
modeling technique would be to undergo a training ses-
sion to tune the kinetic parameters so in silico and in vi-
tro results agree, followed up with an in vitro validation 
experiment (Banks et al., 2003; Jandt et al., 2011). How-
ever, such an approach should be discouraged because 
pharmacokinetic parameters should not change, and 
the overestimate highlights that the model did not ac-
count for other biological effects relevant to transfection. 
Since our model is the first to reconcile the kinetic pa-
rameters for all processes and to simulate DNA trans-
fer up to 48 h, we recognized mitosis and toxicity were 
left unaccounted for in the model, even though their ef-
fects are evident in in vitro experiments (Supplemen-
tary Figure S1, see below) (Lappalainen et al., 1997) and 
known to affect transfection (Brunner et al., 2000; Haka-
mada and Miyake, 2012; Martin et al., 2013). Longer 
time frames are more representative of time points for 
in vitro experiments and therefore mitosis and toxicity 
effects were incorporated into the model and then used 
for simulations.   
 
Solely Incorporating Mitosis in the Model 
Mitosis has been shown in many reports to affect 
the transfection process (Brunner et al., 2000; Haka-
mada and Miyake, 2012), but the effect has never been 
quantified or included in a nonviral gene delivery 
model. Therefore in vitro experiments using WST-1 pro-
liferation assay were conducted on control cells to de-
termine the mitosis rate of HeLa cells in an in vitro cul-
ture system (Supplementary Figure S1). The doubling 
time for HeLa cells is approximately 18 h and there-
fore, one would expect a 100% increase in the number 
of cells in the experiment every 18 h. However, accord-
ing to the WST-1 cell proliferation assay, we observed 
an increase in cells in the experiment of approximately 
2.3% per hour, or 41.4% every 18 h (Supplementary Fig-
ure S1). Possible reasons for the reduced rate of growth 
are lack of space, lowered nutrient availability, or con-
tact-inhibited growth. Some cells also exhibit growth 
rate that is dependent on the plasmid copy number in-
side the cell (Klumpp, 2011). To add these limitations 
to the model, this measured mitosis rate was used and 
was scaled accordingly with the mitosis event initially 
occurring at any random time point within an approx-
imate 18 h time period to recapitulate the in vitro envi-
ronment for non-synced cells. After a cell underwent 
mitosis, the next mitosis event, for a random portion of 
the simulated cells, occurred stochastically with a mean 
of 18 h. After solely incorporating mitosis without toxic-
ity effects in the model simulations, in silico transfection 
level agreed with in vitro levels at the 8 h time point, but 
the model grossly overestimated transfection by 15%, 
25%, and 40% at the 16, 24, and 48 h time points, respec-
tively (Figure 3B). The addition of mitosis to the model 
alone was not enough for the model to accurately pre-
dict in vitro transfection levels, but reduced transfection 
levels compared to the original model (without mitosis 
and without toxicity) were observed (Figure 3A). Likely 
contributions to the reduced transfection levels could 
be dilution of the pDNA and GFP when distributed to 
daughter cells (Gasiorowski and Dean, 2005; James and 
Giorgio, 2000; Tachibana et al., 2004; Varga et al., 2001), 
added exposure of the pDNA to the nucleases during 
Figure 3. The effects of mitosis and toxicity on transfection. The model was initially compiled accounting only for pharmacokinetic parameters (Ta-
ble I), without mitosis and without toxicity (A). Accounting for only mitosis (B) or toxicity (C) resulted in reduced transfection levels. The time points 
on the graph represent model and experimental results after addition of lipoplexes to HeLa cells. Model data, solid line, are reported as mean of 
output from all simulations (see Methods section). Experimental data, dashed line, are reported as the mean ± SEM (n = 6).  
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nuclear breakdown and therefore degradation (Lechar-
deur et al., 1999), pDNA carrier association with mRNA 
which may impede translation (Hama et al., 2007), or 
increase in total number of cells in the experiment and 
therefore a larger divisor in the calculation. Therefore, 
including mitosis alone was not enough for the model to 
accurately predict transfection. 
Solely Incorporating Toxicity in the Model 
Toxicity or cell stress considerations are important in 
the design of the delivery system and have been shown 
to affect transfection (Candiani et al., 2010; Martin et al., 
2013; Plautz et al., 2011; Schweikl et al., 2008). Treatment 
of cells with lipoplexes has been previously reported to 
result in lower total cell numbers, compared to control 
(Lappalainen et al., 1997), or cell senescence (Ludtke et 
al., 2002), but the effect was never quantified nor has it 
ever been included in a model of nonviral gene delivery. 
From in vitro transfection experiments in our lab, those 
cells which exhibit very high GFP fluorescence as ob-
served by Leica DMI 3000B fluorescence microscopy are 
usually rounded, punctate, or detached indicating treat-
ment-induced necrosis, whereas, those cells with rela-
tively lower GFP intensity do not exhibit treatment-in-
duced necrotic morphology (data not shown). Typically, 
as the number of lipoplexes increases in the cell, the 
amount of transgene production increases (i.e., number 
of GFPs) (Tachibana et al., 2004) in addition to increases 
in cytotoxicity in a dose-dependent manner (Lv et al., 
2006). Simulations from our model agree with those ob-
servations (data not shown). Therefore, for the purposes 
of including toxicity in the model, we have linked cell 
death to a relative GFP number and the GFP-induced 
toxicity should be viewed as encompassing all sources 
of toxicity in the cell, not just due to folded GFP protein 
in the cell as the name may infer. The toxicity effect on 
cell growth was determined by assaying lipoplex-treated 
cells using WST-1 toxicity assay (Supplementary Figure 
S1), which showed that approximately 1.2% of cells are 
lost each hour due to treatment-induced toxicity. In order 
to achieve the same effect in the in silico model, toxicity 
was incorporated by removing those cells from the simu-
lation with overproduction of GFP in a Bernoulli distrib-
uted manner. At each 0.5 s increment of the simulation, 
an increasing probability of cell death was determined 
for those cells with greater than 500 GFPs:  
             0,          n ≤ 500
         PD(n) = {             erf (n – 500),   n > 500    (6) 
        
2000
Using that equation, the relative number of GFPs 
used in silico was able recapitulate the approximately 
1.2% loss of cells per hour observed in the in vitro ex-
periment for toxicity (Supplementary Figure S1; data 
not shown). The reason for reduced cell proliferation af-
ter lipoplex treatment is unknown, but protein synthe-
sis is energy-intensive and overproduction of the trans-
gene may lead to a starvation condition in which the cell 
cannot effectively adapt (Jewett et al., 2009). After solely 
incorporating toxicity without mitosis effects in model 
simulations, in silico transfection levels more closely fol-
lowed in vitro transfection levels at 8, 16, and 24 h time 
points but the model grossly overestimated transfection 
by 40% at the 48 h time point (Figure 3C). The observed 
transfection profile appeared erratic because shortly af-
ter a plasmid reaches the nucleus, the GFP transgene is 
rapidly produced and accumulates to levels that lead to 
cell death. Therefore, oscillations in transfection are ob-
served because an increase in transfection is shortly fol-
lowed by death of that transfected cell. Dead cells are 
not considered in calculations, and as a result, over time 
the number of cells in the experiment drastically drops 
and those oscillations appear more drastic after 40 h 
(Figure 3C). Therefore, including toxicity alone was not 
enough for the model to accurately predict transfection. 
The Effect of Mitosis and Toxicity in the Model on 
Transfection 
When toxicity and mitosis were both added to the 
model, reported transfection efficiency was approxi-
mately 30% after 24 h and was not statistically different 
than transfection efficiency measured in in vitro exper-
iments (Figure 4A) at any time point. Including mito-
sis and toxicity in the model had a compound effect in 
reducing transfection efficiency in model simulations. 
Additionally, the oscillations observed in simulations 
from a with-toxicity-without-mitosis model (described 
above; Figure 3C) are not present when mitosis is also 
incorporated into the model due to dilution of cellular 
content from mother cell to daughter cells. These trans-
fection trends reported here for both in silico and in vi-
tro experiments are also similar to transfection efficien-
cies reported for HeLa cells transfected using DOTAP 
(1,2-dioleoyloxy-3-trimethylammoniumpropan):DOPE 
lipoplexes (James and Giorgio, 2000) or TFL-3 lipo-
plexes (Li et al., 2004). In addition to reporting transfec-
tion efficiencies, the number of nuclear-associated plas-
mids has been correlated to transgene expression (James 
and Giorgio, 2000); therefore we compared the output 
of our model, which includes toxicity and mitosis, to ex-
perimental data in regards to the number of nuclear pD-
NAs (Figure 4B), which demonstrated that these num-
bers were not statistically different between in silico and 
in vitro experiments. These results agree with other re-
ports showing the peak number of nuclear plasmids 
to occur at 8 h (~2,000 plasmids/nucleus) and decrease 
slowly 24 h (~1,200 plasmids/nucleus) after initial deliv-
ery of lipoplexes to HeLa cells (Banks et al., 2003; James 
and Giorgio, 2000; Li et al., 2004). A lag in the peak num-
ber of plasmids compared to peak transfection was ob-
served (Figure 4A and B), which is an effect commonly 
reported for lipoplexes (Banks et al., 2003; Tachibana et 
al., 2004). Together, the simulation results for toxicity 
and mitosis potentially highlights the significance of se-
nescence (Ludtke et al., 2002) and GFP-induced necrosis 
on transfection success (Moriguchi et al., 2008).   
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Toxicity Threshold Effect on Cell Viability and 
Transfection 
Since our new telecommunication model of gene deliv-
ery can accurately predict in vitro experiments when 
mitosis and toxicity are included in the model, we next 
set out to explore their effect on transfection (Figure 5A 
and B) by varying the threshold for GFP-induced tox-
icity (see Methods section). The simulations show that 
increasing the threshold for toxicity-induced cell death 
with GFP overproduction results in improved cell via-
bility and increased transfection efficiency from ~30% 
to ~70%, when the toxicity effect is reduced eightfold 
from 500 GFPs to 4,000 GFPs (Figure 5A and B). These 
Figure 4. Model agrees with experimental results. The model was modified to include mitosis and toxicity effect and output was compared to in vi-
tro results at the indicated time points after lipoplex delivery to HeLa cells. Transfection efficiency was measured using FACS (A) or the number of 
plasmids per nucleus was quantified using qRT-PCR (B). Model data, solid line or white bars, are reported as mean of output from all simulations. 
Experimental data, dashed line or filled bars, are reported as the mean ± SEM (n = 6). Chi-square test confirms no statistical difference between the 
model and experimental results with an α = 0.05. 
Figure 5. Toxicity threshold effect on cell viability and transfection. Output from model simulations are shown after the threshold of GFP toxicity-in-
duced cell death was varied to be greater than 500 (dashed line), 1,000 (X mark), 2,000 (filled circle), or 4,000 (solid line) GFPs. Predicted cell via-
bility (A) and transfection efficiency (B) increased as the threshold for GFP-induced toxicity increases.  
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results suggest that it is better to deliver a fewer number 
of plasmids to more cells (and therefore limit the total 
number of GFPs expressed per cell while keeping total 
transgene production high) as opposed to a larger dose 
to fewer cells, consistent with recommendations from 
another report (Moriguchi et al., 2008). Therefore, tox-
icity induced by overproduction of the transgene prod-
uct should be considered in the design of transfection 
systems.   
Model Parameter Sensitivity 
A commonly employed technique to identify those com-
ponents of the model which most affect transfection is 
to perform a sensitivity analysis (Saltelli et al., 2000), 
achieved by varying each parameter in the model and 
measuring the effect on the output (see Methods sec-
tion). The three parameters with the largest relative sen-
sitivity were endosomal escape Δµ2, lysosomal degrada-
tion Δµ3, and protein (matured) degradation Δµ17 with 
relative sensitivities of 1.79, 1.97, and 1.43, respectively 
(Figure 6). Endosomal escape and lysosomal degrada-
tion are believed to be a major barrier to efficient gene 
transfer (Wiethoff and Middaugh, 2003) and were also 
found to be the most sensitive of parameters in a com-
putation model of Lipofectamine-mediated delivery 
of pBGal to C3A hepatocellular carcinoma cells (Varga 
et al., 2005). Improving endosomal escape and reduc-
ing lysosomal degradation of pDNA would result in 
increased cytoplasmic plasmids, an effect shown to re-
sult in increased transfection levels (Fasbender et al., 
1997; Pollard et al., 1998; Tachibana et al., 2004), pre-
sumably through eventual increases in nuclear plasmids 
(James and Giorgio, 2000); such a process may be pDNA 
carrier- (Pollard et al., 1998) or cell type- dependent 
(Hyvonen et al., 2012). Degradation of the folded trans-
gene product was also a sensitive parameter (Figure 6) 
and provides a target for improved transfection. Post-
nuclear processing of the pDNA that might unfavorably 
affect transgene expression has recently become an im-
portant consideration in the design of the transfection 
system (Hama et al., 2007; Hyvonen et al., 2012; Jacob-
sen et al., 2009; Tachibana et al., 2004). The effect of this 
parameter on transfection may be explained by reports 
showing activation of HSP70B’, a molecular chaperone 
involved in protein folding and stability, to result in en-
hanced transfection by several fold (Martin et al., 2013; 
Plautz et al., 2011). Alternatively, an excess of unfolded 
proteins will activate the unfolded protein response 
(UPR), potentially leading to toxicity-induced cell death 
(Lee et al., 2003), which according to our model would 
lead to a reduction in transfection (Figure 5B). Taken to-
gether, endosomal escape, lysosomal degradation, and 
transgene product degradation provide targets for en-
hancing transfection.   
Theoretical Improvements 
The model simulations, as well as these sensitivity re-
sults, offer recommendations for specific barriers that 
future physicochemical modifications of nanoparti-
cle systems for nonviral gene delivery should target 
(or help overcome) (Blessing et al., 2001; Ogris et al., 
2003). Therefore, the potentially achievable changes to 
the gene delivery system for the most sensitive parame-
ters (toxicity-induced GFP threshold, endosomal escape 
Δµ2, lysosomal degradation Δµ3, protein (matured) deg-
radation Δµ17) were evaluated for their effect on trans-
fection (Figure 7). When endosomal escape kinetics 
were increased to 1.7 × 10−2 [similar to adenoviral kinet-
ics (Varga et al., 2005)], transfection efficiency increased 
from 30% to 75%, 48 h after delivery of the complex. 
Similarly, decreasing lysosomal degradation to 1.7 × 10−4 
[which may be accomplished through dodecylation of 
Figure 6. Sensitivity analysis. Each parameter was varied and the resulting transfection efficiencies at the 48 h time point were compared to trans-
fection using baseline parameters (Table I; see Methods section).  
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DNA carrier (Varga et al., 2005)] resulted in an increase 
in transfection efficiency from 30% to 40%. Decreasing 
protein (folded) degradation to 2.1 × 10−8 [e.g., protein 
mutants which stabilize conserved residues (Sacchetti 
et al., 2001)] resulted in no change in transfection, sug-
gesting that this parameter alone cannot affect transfec-
tion, or an alternative improvement method is needed 
to fully capitalize on the parameter sensitivity to trans-
fection, such as cell priming opposed to changes to the 
delivery system (Martin et al., 2013; Plautz et al., 2011). 
Meanwhile improving toxicity-induced threshold by 
twofold [e.g., reducing free DNA carrier (Godbey et al., 
1999, 2001), DNA carrier coatings (Kneuer et al., 2000), 
or altering 5’ untranslated regions and Kozak sequences 
(Sacchetti et al., 2001; Sniegowski et al., 2005)] resulted 
in transfection increases from 30% to 45%. When all of 
the changes to the gene delivery system are applied in 
combination, the predicted transfection efficiency in-
creases threefold, up to 90% after 24 h (Figure 7). Taken 
together, endosomal escape, lysosomal degradation, 
degradation of transgene product, and toxicity induced 
by transgene overproduction provide targets to engi-
neer the gene delivery system for enhanced transfection. 
Conclusions 
Nonviral gene delivery systems need to be improved 
in order to reach therapeutically relevant levels of pro-
tein production. The design process of new gene deliv-
ery systems is quite empirical, often confounded by a 
design change that is an advantage to overcoming one 
barrier but a disadvantage to overcoming another bar-
rier (Li et al., 2004), and the effects on pDNA routing 
throughout the cell remain difficult to predict. Model-
ing allows for easy visualization of how changes to the 
gene delivery system can influence subcellular distri-
bution of pDNA, and more importantly, the effect on 
transgene production. Current models of gene delivery 
have provided valuable information, but challenges re-
main such as representing pDNA transfer with fuller 
scope and longer time frames, including those biologi-
cal processes (e.g., mitosis and toxicity) that occur dur-
ing longer time frames. Current models typically em-
ploy continuous and deterministic modeling methods; 
therefore, we present an alternative modeling technique 
that is discrete and stochastic, in order to open new per-
spectives and propose possible pathways for systematic 
improvement of nonviral gene delivery. Our novel ap-
plication of a telecommunication model of gene delivery 
overcomes these challenges, describing the entire trans-
fection process in one model, accounting for transfec-
tion up to 48 h, and including the mitosis and toxicity ef-
fect on transfection. The model can be easily adapted for 
other carriers by describing pDNA carrier-dependent 
kinetic parameters such as uptake, endosomal escape, 
vesicular degradation, nuclear import protein-to-vec-
tor binding, and unpackaging (Varga et al., 2005). The 
effect of complex type and size on internalization route 
or intracellular routing can also be considered [i.e., cus-
tomer priority, a very important feature of queuing net-
works (Ross, 2000)]. The insight into the mechanisms of 
nonviral pDNA transfer gained from this work provides 
recommendations for better design of gene delivery sys-
tems that can achieve therapeutically relevant transfec-
tion levels.  
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Figure S1 Toxicity induced by lipoplexes. HeLa cells were treated with lipoplexes (circles) and 
at the indicated time points colorimetric measurements for cell proliferation and cell viability 
were taken. Control cells (squares) were not treated with lipoplexes. A linear regression was 
fitted to the data points for treated (dashed line; y = -0.024x + 2.0056, R
2
 = 0.69) and control 
(solid line; y = 0.0412x + 1.4428, R
2
 = 0.97) measurements. The slope of each line was used to 
adjust rate of mitosis and toxicity threshold in model simulations (see Theoretical Aspects). Data 
are reported as the mean ± SEM (n = 3 for control; n = 6 for treated). 
